In today’s session Mylan NV (MYL) recorded an unusually high (781) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the January, 2017 put, expecting serious MYL decrease. With 781 contracts traded and 24414 open interest for the Jan, 17 contract, it seems this is a quite bearish bet. The option with symbol: MYL170120P00043000 closed last at: $7.2 or 14.3% up. About 1.29M shares traded hands. Mylan NV (NASDAQ:MYL) has declined 20.64% since March 15, 2016 and is downtrending. It has underperformed by 26.13% the S&P500.
Analysts await Mylan NV (NASDAQ:MYL) to report earnings on November, 4. They expect $1.60 EPS, up 11.89% or $0.17 from last year’s $1.43 per share. MYL’s profit will be $855.70M for 5.77 P/E if the $1.60 EPS becomes a reality. After $1.16 actual EPS reported by Mylan NV for the previous quarter, Wall Street now forecasts 37.93% EPS growth.
Mylan NV (NASDAQ:MYL) Ratings Coverage
Out of 15 analysts covering Mylan Inc. (NASDAQ:MYL), 9 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 60% are positive. $85 is the highest target while $46 is the lowest. The $60.57 average target is 64.10% above today’s ($36.91) stock price. Mylan Inc. has been the topic of 26 analyst reports since July 27, 2015 according to StockzIntelligence Inc. On Monday, September 21 the stock rating was initiated by Barclays Capital with “Equal Weight”. The rating was maintained by RBC Capital Markets on Tuesday, September 6 with “Sector Perform”. Leerink Swann maintained the stock with “Outperform” rating in Wednesday, May 4 report. On Monday, August 17 the stock rating was downgraded by Zacks to “Buy”. Raymond James upgraded Mylan NV (NASDAQ:MYL) on Monday, October 10 to “Strong Buy” rating. The stock of Mylan NV (NASDAQ:MYL) has “Outperform” rating given on Monday, August 15 by Leerink Swann. The firm has “Buy” rating given on Monday, October 10 by UBS. Morgan Stanley reinitiated the shares of MYL in a report on Thursday, December 3 with “Equal-Weight” rating. Wells Fargo initiated Mylan NV (NASDAQ:MYL) on Friday, February 19 with “Market Perform” rating. The stock of Mylan NV (NASDAQ:MYL) earned “Buy” rating by Standpoint Research on Wednesday, August 26.
According to Zacks Investment Research, “Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.”
Insitutional Activity: The institutional sentiment decreased to 0.45 in 2016 Q2. Its down 0.05, from 0.5 in 2016Q1. The ratio dived, as 6 funds sold all Mylan NV shares owned while 5 reduced positions. 1 funds bought stakes while 4 increased positions. They now own 533,685 shares or 37.96% less from 860,251 shares in 2016Q1.
Icon Advisers owns 35,000 shares or 0.1% of their US portfolio. The Connecticut-based Westport Res has invested 0.37% in Mylan NV (NASDAQ:MYL). Eagle Asset Mgmt Inc has 0.02% invested in the company for 56,209 shares. Jacobs And Ca holds 7,305 shares or 0.07% of its portfolio. Vantage Advsr Ltd Llc last reported 712 shares in the company. Covington Mngmt holds 39,339 shares or 0.16% of its portfolio. Ntv Asset Limited Liability Company has 0.26% invested in the company for 15,990 shares. Gemmer Asset Mgmt Ltd Company holds 0% or 21 shares in its portfolio. Gulf Fincl Bank (Uk) Limited has invested 0.09% of its portfolio in Mylan NV (NASDAQ:MYL). Amer Research And Mngmt has 1,600 shares for 0.03% of their US portfolio. Princeton Portfolio Strategies Gp Inc Lc holds 135,477 shares or 1.89% of its portfolio. Novare Capital Management Limited Co has 0.93% invested in the company for 79,851 shares.
Mylan N.V. is a global pharmaceutical company. The company has a market cap of $19.74 billion. The Firm develops, licenses, makes, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients . It has a 23.46 P/E ratio. It operates through two divisions: Generics and Specialty.
MYL Company Profile
Mylan N.V., incorporated on July 7, 2014, is a global pharmaceutical company. The Firm develops, licenses, makes, markets and distributes generic, branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). The Firm operates through two divisions: Generics and Specialty. The principal markets for Generics are pharmaceutical wholesalers and distributors; group purchasing organizations; drug store chains; independent pharmacies; drug manufacturers; institutions, and public and governmental agencies primarily within the United States and Canada (collectively, North America); Europe, and India, Australia, Japan, New Zealand and Brazil (collectively, Rest of World). The Generics segment also focuses on developing API with non-infringing processes for both internal use and to partner with manufacturers in regulated markets, such as the United States and the European Union at market formation. The principal market for Specialty is pharmaceutical wholesalers and distributors, pharmacies and healthcare institutions primarily in the United States.
More notable recent Mylan NV (NASDAQ:MYL) news were published by: Wsj.com which released: “Mylan to Pay $465 Million to Settle Medicaid Claims” on October 07, 2016, also Investorplace.com with their article: “The Mylan NV (MYL) Stock Relief Rally Won’t Last Long” published on October 11, 2016, Prnewswire.com published: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on October 06, 2016. More interesting news about Mylan NV (NASDAQ:MYL) were released by: Investorplace.com and their article: “3 Stocks to Watch Monday: Mylan NV (MYL), Bristol-Myers Squibb Co (BMY) and …” published on October 10, 2016 as well as Wsj.com‘s news article titled: “Mylan’s EpiPen Pretax Profits 60% Higher Than Number Told to Congress” with publication date: September 26, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.